Form 4: Altimmune Officer M. Scot Roberts Acquires Shares Through Employee Stock Purchase Plan
SEC Form 4 Filing
Altimmune's Chief Scientific Officer, M. Scot Roberts, acquired 650 shares of common stock through the company's Employee Stock Purchase Plan (ESPP) at a price of $5.41 per share on July 31, 2024.
Summary
- On July 31, 2024, M. Scot Roberts, Chief Scientific Officer of Altimmune, Inc., acquired 650 shares of Altimmune's common stock through the company's Employee Stock Purchase Plan (ESPP).
- The purchase price was $5.41 per share, based on 85% of the closing price of Altimmune's common stock on July 31, 2024, as per the ESPP terms.
- Following the transaction, Roberts directly owns 43,310 shares of Altimmune's common stock.
- Roberts also indirectly owns 15 shares of Altimmune's common stock through his spouse.
- A Power of Attorney document was also filed, authorizing Vipin K. Garg and Andrew Shutterly to act on Roberts' behalf for SEC filings.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. The purchase of shares by an officer is generally a good sign, but it's part of a routine ESPP, so the impact is limited.
Positives
- The purchase of shares by a company officer through the ESPP could be seen as a positive signal, indicating confidence in the company's future prospects.
Industry Context
Insider transactions are closely monitored by investors as they can provide insights into management's perspective on the company's valuation and future performance. Purchases, especially by high-ranking officers, are often viewed positively.
Comparison to Industry Standards
- Comparing insider trading activity at Altimmune to similar biotech companies like Madrigal Pharmaceuticals or Viking Therapeutics could provide context on whether this level of insider buying is typical.
- Reviewing the ESPP participation rates across the biotech industry can help determine if Altimmune's ESPP is structured competitively.
Stakeholder Impact
- The transaction could have a minor positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| February 1, 2024 | Start date of the ESPP purchase period. |
| July 31, 2024 | Date of the stock purchase transaction and end of the ESPP purchase period. |
| August 1, 2024 | Date of the Power of Attorney execution and Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.